BOWDISH KATHERINE S has a total of 21 patent applications. Its first patent ever was published in 2003. It filed its patents most often in United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are ADRENOMED AG, IGAKU SEIBUTSUGAKU KENKYUSHO KK and ADURO BIOTECH HOLDINGS EUROP B V.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 21 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Foods and drinks | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Microorganisms | |
#6 | Climate change adaptation technologies | |
#7 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Bowdish Katherine S | 21 |
#2 | Kretz-Rommel Anke | 13 |
#3 | Mcwhirter John | 5 |
#4 | Dakappagari Naveen | 4 |
#5 | Renshaw Mark | 3 |
#6 | Maruyama Toshiaki | 2 |
#7 | Frederickson Shana | 2 |
#8 | Faas Mcknight Susan | 2 |
#9 | Wu Dayang | 2 |
#10 | Springhorn Jeremy P | 2 |
Publication | Filing date | Title |
---|---|---|
US2016031985A1 | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
US2008008719A1 | Methods and compositions for the treatment of prostate cancer | |
US2006057651A1 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
US2005281828A1 | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells | |
US2005208627A1 | Elicitation of antibodies to self peptides in mice by immunization with dendritic cells | |
US9249229B2 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |